Bal Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bal Pharma Ltd. on BSE

Load latest

Bal Pharma Ltd.

22 Mar 2024

108.34

19.99%

SAST

BAL PHARMA LTD. - 524824 - Closure of Trading Window

BSE India

Pursuant to the Code of Conduct of the Company and as per the amended provisions of SEBI(Prohibition of Insider Trading) Regulations,2015, We wish to inform the exchanges that the trading window for dealing with the securities of the Company on the designated persons and their immediate relatives will be closed from 1st April 2024 and up to 48 hours of the declaration of the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2024. The date of the Board meeting for declaration of audited financial results will be intimated to the exchanges in due course.

pdf

Bal Pharma Ltd.

14 Feb 2024

108.34

19.99%

Company Update

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

We are submitting to the exchanges copies of the newspaper advertisements of abridged standalone and consolidated financial results of the Company for the quarter and nine months ended 31.12.2023, announced by the Company on 12.02.2024 and published in Financial Express ( English) and Sanjayvani ( Kannada ) on 13.02.2024.

pdf

Bal Pharma Ltd.

12 Feb 2024

108.34

19.99%

Board Meeting

BAL PHARMA LTD. - 524824 - Board Meeting Outcome for Unaudited Financial Results For The Quarter …

BSE India

1. Taken on record and approved the Un-Audited Standalone and Consolidated Financial Results of the Company for the Quarter and 9 Months ended 31.12.2023. A copy of the approved financial results together with Limited Review Reports issued by the statutory auditors of the company with unmodified opinion is enclosed with this intimation. 2. The Board has considered and acknowledged the receipt of letter of allotment from KIADB allotting 5 acres of land to the company at Kadechur KIADB industrial area, Yadgiri, Karnataka. The proposed project for setting up of the API and Intermediaries manufacturing facility at the above said industrial are was approved at the State Level Single Window Clearance Committee, Government of Karnataka.

pdf

Bal Pharma Ltd.

12 Feb 2024

108.34

19.99%

Result

BAL PHARMA LTD. - 524824 - Unaudited Financial Results For The Quarter Ended 31.12.2023.

BSE India

Unaudited standalone and consolidated Financial results for the quarter and 9 months ended 31.12.2023.

pdf

Bal Pharma Ltd.

25 Jan 2024

108.34

19.99%

Board Meeting

BAL PHARMA LTD. - 524824 - Board Meeting Intimation for 1)Approval Of Un-Audited Financial Results Of …

BSE India

BAL PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/02/2024 ,inter alia, to consider and approve 1) Un-Audited Standalone and Consolidated financial results of the Company for the quarter and nine months ended 31.12.2023. 2)To consider investing additional capital in expanding its manufacturing presence , through a green field project.

pdf

Bal Pharma Ltd.

02 Jan 2024, 12:45PM

108.34

19.99%

Company Update

BAL PHARMA LTD. - 524824 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

We are submitting the certificate as per Regulation 74(5) of SEBI ( DP) Regulations, for the quarter ended 31.12.2023.

pdf

Bal Pharma Ltd.

28 Dec 2023

108.34

19.99%

SAST

BAL PHARMA LTD. - 524824 - Closure of Trading Window

BSE India

We wish to inform the exchanges that the trading window for dealing with the securities of the Company on the designated employees and their relatives will be closed from 1st January 2024 and up to 48 hours of the declaration of the un-audited financial results of the Company for the quarter and nine months ended 31.12.2023. The date of declaration of un-audited financial results will be intimated to the exchanges in due course.

pdf

Bal Pharma Ltd.

22 Dec 2023

108.34

19.99%

AGM

BAL PHARMA LTD. - 524824 - Shareholder Meeting / Postal Ballot-Scrutinizer"s Report

BSE India

We are submitting to the exchange a copy of the scrutinizers report on the e-voting results of the NCLT convened shareholders meeting of the company held on 21.12.2023. Please take the same on record.

pdf

Bal Pharma Ltd.

21 Dec 2023

108.34

19.99%

AGM

BAL PHARMA LTD. - 524824 - Shareholder Meeting / Postal Ballot-Outcome of Court Convened Meeting

BSE India

Pursuant to the provisions of Regulation 30 of SEBI (LODR) Regulations ,2015, we are submitting to the exchanges business transacted at the NCLT convened meetings of shareholders, secured and unsecured creditors of the Company, which was conducted through audio visual means on 21.12.2023

pdf

Bal Pharma Ltd.

21 Nov 2023

108.34

19.99%

Company Update

BAL PHARMA LTD. - 524824 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

We are submitting to the exchanges newspaper publication of the Notice issued to the Shareholders and Creditors of Bal Pharma Ltd (Transferee Company) and its wholly owned subsidiary Golden Drugs Pvt Ltd (Transferer Company) for the NCLT convened meetings scheduled on 21.12.2023 and published in Financial Express (English) and Vijayavani (Kannada), on 20.11.2023.

pdf

No results found

Is Bal Pharma Ltd. worth buying?

52 Votes:

Buy 76.92%

Sell 13.46%

Hold 9.62%

31.42% Fall from 52W High

High volume+gain today

Bal Pharma Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Bal Pharma Ltd. on BSE